Gastrointestinal stromal tumors (GIST): Clinical aspects;Tumores de la estroma gastrointestinal (GIST): Aspectos clínicos

Revista Espanola de Enfermedades Digestivas

Volumn 99, Issue 1, 2007, Pages 19-24

  Fernandez Salazar L I ^a,b   Alvarez Gago T ^a   Sanz Rubiales, A ^a   Velayos Jimenez B ^a   Aller De La Fuente, R ^a   Gonzalez Hernandez J M ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^b NONE   (Spain)

Author keywords

c KIT; GIST; Mesenchymal tumor

Indexed keywords

IMATINIB;

ABDOMINAL PAIN; ADULT; AGED; AGGRESSION; ARTICLE; CANCER RELAPSE; CANCER RISK; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DISEASE COURSE; ECHOGRAPHY; FEMALE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; LAPAROTOMY; MALE; TUMOR VOLUME; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED;

EID: 34247603201     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Miettinen M, Majidi M, Lasota J. Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. Eur J Cancer 2002; 33: S39.
2. Solis-Herruzo JA, Solis-Muñoz P. GISTs: from the molecular knowledge to the rational treatment. Rev Esp Enferm Dig 2003; 95: 677-82.
3. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002; 33: 459-65.
4. Nilsson B, Bumming P, Meis-Kindblom JM, Orden A, Dortok A, Gustavsson B, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era- a population-base study in western Sweden. Cancer 2005; 103: 821-9.
5. Goettsch WG, Bos SD, Breekveldt-Postma N, Caspaire M, Herings RM, Hogendoorn PC. Incidence of gastrointestinal stromal tumors is underestimated: results of a nation-wide study. Eur J Cancer 2005; 41: 2868-72.
6. Sircar K, Hewlett BR, Huizinga JD, Chorneyko K, Berezin I, Riddell RH. Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors. Am J Surg Pathol 1999; 23: 377-89.
7. Sanders KM. A case of interstitial cells of Cajal as pacemakers and mediators of neurotransmission in the gastrointestinal tract. Gastroenterology 1996; 111: 492-515.
8. Miettinen M, Lasota J. Gastrointestinal stromal tumors -definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchow Arch 2001; 438: 1-12.
9. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1988; 279: 577-80.
10. Miettinen M, Monihan JM, Sarlomo-Rikala M, Kovatich AJ, Carr NJ, Emory TS, et al. Gastrointestinal stromal tumors /smooth muscle tumors / GISTs in the omentum and mesentery -clinicopathologic and immunohistochemical study of 26 cases. Am J Surg Pathol 1999; 23: 1109-18.
11. Emory TS, Sobin LH, Lukes L, Lee DH, O'Leary TJ. Prognosis of gastrointestinal smooth muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol 1999; 23: 82-7.
12. Agaimy A, Wuensch PH. Gastrointestinal stromal tumors in patients with other-type cancer: a mere coincidence or an etiological association? A study of 97 GIST cases. Z Gastroenterol 2005; 43: 1025-30.
13. Kalmar K, Tornoczky T, Poto L, Illenyi L, Kalmar Nagy K, Kassaie M, et al. Gastrointestinal stromal tumors in a single institute: is there an association to other gastrointestinal malignanacies? Mgy Seb 2004; 57: 251-6.
14. De Matteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brenan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231: 51-8.
15. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long term follow-up. Am J Surg Pathol 2005; 29: 52-68.
16. De Francisco R, Díaz G, Cadahía V, Velázquez RF, Giganto F, González O, et al. Lower GI bleeding secondary to a stromal rectal tumor (rectal GIST). Rev Esp Enferm Dig 2006; 98: 387-8.
17. Pesqueira Fontán PM, Molinos Castro S, Caro Narrillos C, Pardavila Gómez R. Hepatic metastases: a way of GIST presentation. Rev Esp Enferm Dig 2006; 98: 147-9.
18. Pardo Martínez C, Mayol Martínez J, Hernández Pérez C, Álvarez Fernández-Represa J. Gastric stromal tumors: clinical presentation and clinical options. Rev Esp Enferm Dig 2004; 96: 578-81.
19. Miettinen M, Sobin LH, Sarlomo-Rikala M. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a referente to CD 117 (KIT). Mod Pathol 2000; 13: 1134-42.
20. Hasegawa T, Matsuno Y, Shimoda T, Hirohashi S. Gastrointestinal stromal tumor: Consistent CD117 immunostaining for diagnosis, and prognostic classification based on tumor size and MIB-1 grade. Hum Pathol 2002; 33: 669-76.
21. Singer S, Rubin BP, Lux ML, Chen CJ, Demetri GD, Fletcher CD, et al. Prognostic value of KIT mutation type, mitotic activity, and hystologic subtype in gastrointestinal stromal tumors. J Clin Oncol 2002; 20: 3898-905.
22. Koay MH, Goh YW, Iacopetta B, Grieu F, Segal A, Sterrett GF, et al. Gastrointrestinal stromal tumours (GISTs): a clinicopathological and molecular study of 66 cases. Pathology 2005; 37: 22-31.
23. Tzen CY, Mau BL. Analysis of CD117-negative gastrointestinal stromal tumors. World J Gastroenterol 2005; 11: 1052-5.
24. Feakins RM. The expression of p-53 and bcl-2 in gastrointestinal stromal tumors is associated with anatomical site, and p53 expression is associated with grade and clinical outcome. Histopathology 2005; 46: 270-9.
25. Nakamura N, YamamotoH, Yao T, Oda Y, Nishiyama K, Imamura M, et al. Prognostic significance of cell-cycle regulatory proteins in gastrointestinal stromal tumor and the relevance of the risk grade. Hum Pathol 2005; 36: 828-37.
26. Aparicio T, Boige V, Sabourin JC, Crenn P, Ducreux M, Le Cesne A, et al. Prognostic factors alter surgery resectable gastrointestinal stromal tumors. Eur J Surg Oncol 2004; 30: 1098-103.
27. Connolly EM, Gaffney E, Reynolds JV. Gastrointestinal stromal tumors. Br J Surg 2003; 90: 1178-86.
28. Emile JF, Theou N, Tabone S, Cortez A, Terrier P, Chaumette, MT, et al. Clinicopathologic phenotypic and genotypic characteristics of gastrointestinal mesenchymal tumors. Clin Gastroenterol Hepatol 2004: 2: 597-605.
29. Verweij J, Casali PG, Zalcberg J, Le Cesne A, Reichardt P, Blay JY, et al. Progression-free survival in gastrointestinal stromal tumors with high-dose Imatinib: a randomised trial. Lancet 2004; 364: 1127-34.
30. Rankin C, von Mehren M, Blanke C, et al. Dose effect of Imatinib in patients with metastatic GIST-Phase III Sarcoma Intergroup Study (abstract). Proc Am Soc Clin Oncol 2004; 23: 815a.
31. Fernández A, Aparicio J. Imatinib and gastrointestinal stromal tumor (GIST): a selective targeted therapy. Rev Esp Enferm Dig 2004; 96: 723-6.
32. Blay JY, Bonvalot S, Casali P, Choi H, Debiec-Richter M, Dei Tos AP, et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus conference of 20-21 march 2004, under the auspices of ESMO. Ann Oncol 2005; 16: 566-78.
33. Chen LL, Sabripour M, Andtbacka RH, Patel SR, Feig BW, Macapinlae HA, et al. Imatinib resistance in gastrointestinal stromal tumors. Curr Oncol Rep 2005; 7: 293-9.
34. Van Glabbeke M, Verweij J, Casali PG, et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for research and treatment of cancer-Italian sarcoma group-Australasian gastrointestinal trials group. J Clin Oncol 2005; 23: 5795-804.
35. Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B, et al. Acquired resistance to imatinib in gastrointestinal stromal tumors through secondary gene mutation. Clin Cancer Res 2005; 11: 4182-90.
36. Zalcberg JR, Verweij J, Casali PG, Le Cesne A, Reichardt P, Blay JY, et al. Outcome of patients with advanced gastro-intestinal stromal tumors crossing over to a daily imatinib dose of 800 mg alter progression on 400 mg. Eur J Cancer 2005; 41: 1751-7.
37. Demetri GD, Desai J, Fletcher JA. SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome Imatinib resistance caused by diverse genomic mechanisms in patients with metastatic gastrointestinal stromal tumor (abstract). Proc Am Soc Clin Oncol 2004; 22: 195s.